Hydroxychloroquine: From malaria to autoimmunity

Clinical Reviews in Allergy and Immunology

Volumn 42, Issue 2, 2012, Pages 145-153

  Ben Zvi, Ilan ^a   Kivity, Shaye ^a   Langevitz, Pnina ^a   Shoenfeld, Yehuda ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antimalarial; Chloroquine; Hydroxychloroquine; Lupus; Novel; Therapy

Indexed keywords

ARACHIDONIC ACID; CASPASE 3; CHLOROQUINE; HEMOGLOBIN; HYDROXYCHLOROQUINE; INSULIN; PROTEIN BAX; PROTEIN BCL 2;

ABDOMINAL CRAMP; AGRANULOCYTOSIS; ALKALINIZATION; ALOPECIA; ANGIONEUROTIC EDEMA; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTICOAGULATION; ANTIDIABETIC ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APLASTIC ANEMIA; APOPTOSIS; ATAXIA; AUTOIMMUNITY; BLURRED VISION; BRONCHOSPASM; BURKITT LYMPHOMA; CARDIOMYOPATHY; CARDIOVASCULAR EFFECT; CELL ORGANELLE; CHRONIC LYMPHATIC LEUKEMIA; CORNEA INJURY; CORONAVIRUS; DERMATOMYOSITIS; DIABETES MELLITUS; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EMOTIONAL DISORDER; ENZYME ACTIVATION; EOSINOPHILIC FASCIITIS; GRAFT VERSUS HOST REACTION; GRANULOMA ANNULARE; HAIR DISCOLORATION; HEADACHE; HEARING IMPAIRMENT; HEMOLYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOMODULATION; INTRACELLULAR SIGNALING; IRRITABILITY; LASSITUDE; LICHEN PLANUS; LIVER FUNCTION; MALARIA; METABOLIC CAPACITY; MUSCLE ATROPHY; MYOPATHY; NAUSEA AND VOMITING; NERVOUSNESS; NEUROMUSCULAR DISEASE; NIGHTMARE; PANNICULITIS; PARALYSIS; PHOTODERMATOSIS; PIGMENT DISORDER; PORPHYRIA CUTANEA TARDA; PRURITUS; PSORIASIS; PSYCHOSIS; RASH; RESPIRATORY FAILURE; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SIDE EFFECT; SJOEGREN SYNDROME; SKIN PIGMENTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TINNITUS; TREATMENT INDICATION; VERTIGO; VIRUS INHIBITION; VIRUS REPLICATION; WEAKNESS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGEN PRESENTATION; ANTIMALARIALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; CALCIUM SIGNALING; CYTOKINES; HUMANS; HYDROXYCHLOROQUINE; MACROPHAGES; MALARIA; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 84862226725     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-010-8243-x     Document Type: Review

References (111)

1. Smith CD, Cyr M (1988) The history of lupus erythematosus. From Hippocrates to Osler. Rheum Dis Clin North Am 14(1):1-14
2. Mates M, Nesher G, Zevin S (2007) Quinines-past and present. Harefuah 146(7):560-562, 72
3. Wallace DJ (1996) The history ofantimalarials. Lupus 5(Suppl 1): S2-S3
4. Page F (1951) Treatment of lupus erythematosus with mepa-crine. Lancet 2(6687):755-758
5. Clark P, Casas E, Tugwell P, Medina C, Gheno C, Tenorio G et al (1993) Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 119 (11):1067-1071 (Pubitemid 23359919)
6. Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A et al (2002) Protective effect of hydroxychlor-oquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11(6):356-361 (Pubitemid 34760633)
7. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A et al (1998) A long-term study of hydroxychlor-oquine withdrawal on exacerbations in systemic lupus eryth-ematosus. The Canadian Hydroxychloroquine Study Group. Lupus 7(2):80-85 (Pubitemid 28107971)
8. Kalia S, Dutz JP (2007) New concepts in antimalarial use and mode of action in dermatology Dermatol Ther 20(4):160-174 (Pubitemid 350029307)
9. Ohkuma S, Poole B (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 75(7):3327-3331 (Pubitemid 8389720)
10. Ziegler HK, Unanue ER (1982) Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA 79(1):175-178 (Pubitemid 12181509)
11. Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L (1993) Selective regulation of cytokine secretion by hydroxy-chloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 20 (5):803-808 (Pubitemid 23158473)
12. Loffler BM, Bohn E, Hesse B, Kunze H (1985) Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver. Biochim Biophys Acta 835(3):448-455 (Pubitemid 15247856)
13. Manku MS, Horrobin DF (1976) Chloroquine, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists. Lancet 2(7995): 1115-1117
14. Lester RS, Burnham TK, Fine G, Murray K (1967) Immunologic concepts of light reactions in lupus erythematosus and polymor-phous light eruptions. I. The mechanism of action of hydroxy-chloroquine. Arch Dermatol 96(1):1-10
15. Cohen SN, Yielding KL (1965) Spectrophotometric studies of the interaction of chloroquine with deoxyribonucleic acid. J Biol Chem 240:3123-3131
16. Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ (2000) Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomod-ulatory properties. Blood 95(11):3460-3466 (Pubitemid 30428477)
17. Lesiak A, Narbutt J, Sysa-Jedrzejowska A, Lukamowicz J, McCauliffe DP, Wozniacka A (2010) Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus 19(6): 683-688
18. Kyburz D, Brentano F, Gay S (2006) Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2(9): 458-459 (Pubitemid 44340417)
19. YoussefW, Yan A, Russell AS (1991) Palindromic rheumatism: a response to chloroquine. J Rheumatol 18(1):35-37
20. Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB (1988) Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 17(4):221-231
21. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C (1984) Cutaneous lesions of dermatomyositis are improvedby hydroxychloroquine. J Am Acad Dermatol 10(4):592-600 (Pubitemid 14171230)
22. Fox RI, Dixon R, Guarrasi V, Krubel S (1996) Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retro-spective, open-label study. Lupus 5(Suppl 1):S31-S36
23. Ashton RE, Hawk JL, Magnus IA (1984) Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. Br J Dermatol 111(5):609-613 (Pubitemid 15200164)
24. Valls V, Ena J, Enriquez-De-Salamanca R (1994) Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload. J Dermatol Sci 7(3):169-175 (Pubitemid 24210888)
25. Murphy GM, Hawk JL, Magnus IA (1987) Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring. Br J Dermatol 116(3):379-386 (Pubitemid 17030542)
26. Cannistraci C, Lesnoni La Parola I, Falchi M, Picardo M (2005) Treatment of generalized granuloma annulare with hydroxy-chloroquine. Dermatology 211(2):167-168 (Pubitemid 41160258)
27. Eisen D (1993) Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial. J Am Acad Dermatol 28(4):609-612 (Pubitemid 23104237)
28. Chung HS, Hann SK (1997) Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol 24(9):569-572
29. Jessop S, Whitelaw DA, Delamere FM (2009) Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. (4): CD002954
30. Rolain JM, Colson P, Raoult D (2007) Recycling ofchloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30 (4):297-308 (Pubitemid 47364778)
31. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 3(11):722-727 (Pubitemid 37345352)
32. Savarino A, Gennero L, Sperber K, Boelaert JR (2001) The anti-HIV-1 activity ofchloroquine. J Clin Virol 20(3):131-135
33. Savarino A, Lucia MB, Rastrelli E, Rutella S, Golotta C, Morra E et al (2004) Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 35(3):223-232 (Pubitemid 38280647)
34. Sperber K, Kalb TH, Stecher VJ, Banerjee R, Mayer L (1993) Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 9(1):91-98 (Pubitemid 23055136)
35. Paton NI, Aboulhab J (2005) Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med 6(1):13-20 (Pubitemid 40268111)
36. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M (2004) In vitro inhibition of severe acute respiratory syndrome corona-virus by chloroquine. Biochem Biophys Res Commun 323(1): 264-268 (Pubitemid 39200678)
37. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG et al (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69
38. Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M et al (2009) Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 53(8):3416-3421
39. Blazar BR, Whitley CB, Kitabchi AE, Tsai MY, Santiago J, White N et al (1984) In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance. Diabetes 33(12):1133-1137 (Pubitemid 15176843)
40. Smith GD, Amos TA, Mahler R, Peters TJ (1987) Effect of chloroquine on insulin and glucose homoeostasis in normal subjects and patients with non-insulin-dependent diabetes melli-tus. Br Med J (Clin Res Ed) 294(6570):465-467 (Pubitemid 17020453)
41. Quatraro A, Consoli G, Magno M, Caretta F, Nardozza A, Ceriello A et al (1990) Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A newjob for an old drug? Ann Intern Med 112(9):678-681 (Pubitemid 20137177)
42. Gerstein HC, Thorpe KE, Taylor DW, Haynes RB (2002) The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas-a ran-domized trial. Diabetes Res Clin Pract 55(3):209-219 (Pubitemid 34163292)
43. Emami J, Pasutto FM, Mercer JR, Jamali F (1999) Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. Life Sci 64(5):325-335 (Pubitemid 29051521)
44. Powrie JK, Smith GD, Shojaee-Moradie F, Sonksen PH, Jones RH (1991) Mode of action ofchloroquine in patients with non-insulin-dependent diabetes mellitus. Am J Physiol 260(6 Pt 1): E897-E904
45. Shojania K, Koehler BE, Elliott T (1999) Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol 26(1):195-196 (Pubitemid 29051417)
46. Penn SK, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L et al (2010) Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 37(6):1136-1142
47. Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF et al (2007) Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298(2):187-193 (Pubitemid 47057765)
48. Rekedal LR, Massarotti E, Garg R, Bhatia R, Gleeson T, Lu B et al (2010) Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum 62(12):3569-3573
49. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA (1990) Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89(3):322-326 (Pubitemid 20323259)
50. Hodis HN, Quismorio FP Jr, Wickham E, Blankenhorn DH (1993) The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythemato-sus. J Rheumatol 20(4):661-665 (Pubitemid 23138855)
51. Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA (1997) Effect ofdisease modifying agents on the lipid profiles ofpatients with rheumatoid arthritis. Ann Rheum Dis 56 (6):374-377 (Pubitemid 27305426)
52. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN (1999) The cholesterol lowering effect ofantimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 26(2):325-330 (Pubitemid 29066736)
53. Tam LS, Li EK, Lam CW, Tomlinson B (2000) Hydroxychlor-oquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. Lupus 9(6):413-416 (Pubitemid 30487423)
54. Bengtsson C, Andersson SE, Edvinsson L, Edvinsson ML, Sturfelt G, Nived O (2010) Effect of medication on microvas-cular vasodilatation in patients with systemic lupus erythemato-sus. Basic Clin Pharmacol Toxicol 107(6):919-924
55. Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M et al (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Ar-thritis Rheum 62(3):863-868
56. Tanay A, Leibovitz E, Frayman A, Zimlichman R, Shargorodsky M, Gavish D (2007) Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxy-chloroquine treatment. Ann NYAcad Sci 1108:24-34 (Pubitemid 47528715)
57. Johnson R, Charnley J (1979) Hydroxychloroquine in prophy-laxis of pulmonary embolism following hip arthroplasty. Clin Orthop Relat Res 144:174-177
58. Nosal R, Jancinova V, Petrikova M (1995) Chloroquine inhibits stimulated platelets at the arachidonic acid pathway Thromb Res 77(6):531-542
59. Petri M (1996) Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 25 (4):191-193 (Pubitemid 26273848)
60. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM (2009) Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 61(1):29-36
61. Belizna CC, Richard V, Thuillez C, Levesque H, Shoenfeld Y (2007) Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev 7(1):46-51 (Pubitemid 47633391)
62. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD (2002) A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheu-matology (Oxford) 41(8):924-929
63. Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN (1997) Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96 (12):4380-4384 (Pubitemid 28007469)
64. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87 (3):518-522 (Pubitemid 34232495)
65. Rand JH, Wu XX, Quinn AS, Ashton AW, Chen PP, Hathcock JJ et al (2010) Hydroxychloroquine protects the annexin A5 antico-agulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 115 (11):2292-2299
66. Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ (2008) Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 112(5):1687-1695
67. Geser A, Brubaker G, Draper CC (1989) Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma. Am J Epidemiol 129(4):740-752 (Pubitemid 19094252)
68. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB (2008) Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphoma-genesis. J Clin Invest 118(1):79-88
69. Lagneaux L, Delforge A, Carlier S, Massy M, Bernier M, Bron D (2001) Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors. Br J Haematol 112 (2):344-352 (Pubitemid 32183475)
70. Lagneaux L, Delforge A, Dejeneffe M, Massy M, Bernier M, Bron D (2002) Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio. Leuk Lymphoma 43(5):1087-1095 (Pubitemid 34460895)
71. Mansilla E, Marin GH, Nunez L, Drago H, Sturla F, Mertz C et al (2010) The lysosomotropic agent, hydroxychloroquine, deliv-ered in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro. Cancer Biother Radiopharm 25(1):97-103
72. Jiang PD, Zhao YL, Shi W, Deng XQ, Xie G, Mao YQ et al (2008) Cell growth inhibition, G2/M cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Bcap-37. Cell Physiol Biochem 22(5-6):431-440
73. Rahim R, Strobl JS (2009) Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 20(8):736-745
74. Zhou Q, McCracken MA, Strobl JS (2002) Control ofmammary tumor cell growth in vitro by novel cell differentiation and apoptosis agents. Breast Cancer Res Treat 75(2):107-117 (Pubitemid 34994946)
75. Zheng Y Zhao YL, Deng X, Yang S, Mao Y, Li Z et al (2009) Chloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis. Cancer Invest 27 (3):286-292
76. Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y et al (2010) Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 10:370
77. Fan C, Wang W, Zhao B, Zhang S, Miao J (2006) Chloroquine inhibits cell growth and induces cell death in A549 lung cancer cells. Bioorg Med Chem 14(9):3218-3222
78. Sotelo J, Briceno E, Lopez-Gonzalez MA (2006) Adding chloroquine to conventional treatment for glioblastoma multi-forme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144(5):337-343 (Pubitemid 46768188)
79. Hu C, Solomon VR, Ulibarri G, Lee H (2008) The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. Bioorg Med Chem 16(17):7888-7893
80. Solomon VR, Lee H (2009) Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 625(1-3):220-233
81. Schultz KR, Gilman AL (1997) The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. Leuk Lymphoma 24(3-4):201-210 (Pubitemid 27101592)
82. Khoury H, Trinkaus K, Zhang MJ, Adkins D, Brown R, Vij R et al (2003) Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant 9(11):714-721 (Pubitemid 38145755)
83. Fong T, Trinkaus K, Adkins D, Vij R, Devine SM, Tomasson M et al (2007) A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Biol Blood MarrowTransplant 13(10):1201-1206 (Pubitemid 47413019)
84. Chen PH, Huang YF, Tang CW, Wann SR, Chang HT (2010) Kikuchi-Fujimoto disease: an amazing response to hydroxy-chloroquine. Eur J Pediatr 169(12):1557-1559
85. Rezai K, Kuchipudi S, Chundi V, Ariga R, Loew J, Sha BE (2004) Kikuchi-Fujimoto disease: hydroxychloroquine as a treatment. Clin Infect Dis 39(12):e124-e126
86. DeSimone DP, Brilliant HL, Basile J, Bell NH (1989) Granulo-matous infiltration of the talus and abnormal vitamin D and calcium metabolism in a patient with sarcoidosis: successful treatment with hydroxychloroquine. Am J Med 87(6):694-696 (Pubitemid 20006514)
87. O'Leary TJ, Jones G, Yip A, Lohnes D, Cohanim M, Yendt ER (1986) The effects ofchloroquine on serum 1, 25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 315 (12):727-730 (Pubitemid 16054987)
88. Shimoni A, Hershcovici T, Mekhmandarov S, Maor-Kendler Y Beigel Y (2000) Skeletal sarcoidosis: successful treatment with hydroxychloroquine. Isr Med Assoc J 2(7):558-559 (Pubitemid 30611776)
89. Hirshoren N, Eliashar R, Weinberger JM (2010) Hydroxychlor-oquine for subglottic stenosis: a novel therapy in the battle for air. Laryngoscope 120(4):743-744
90. Hussain A, Scelsa SN (2010) Sensory neuronopathy with Ro antibodies: response to combination immunosuppression. J Clin Neuromuscul Dis 11(3):120-123
91. Izmirly PM CP, Kim MY DF, Llanos C, C-C N et al (2010) Hydroxychloroquine and prevention of anti-SSA/Ro associated cardiac disease in mothers with a previous child with Neonatal Lupus. Arthritis Rheum 62(10):S306
92. Izmirly PM, Kim MY, Llanos C, Le PU, Guerra MM, Askanase AD et al (2010) Evaluation of the risk of anti-SSA/Ro-SSB/ La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythemato-sus exposed to hydroxychloroquine. Ann Rheum Dis. doi:10.1136/ard.2009.119263
93. Iyamu E, Perdew H, Woods G (2009) Growth inhibitory and differentiation effects of chloroquine and its analogue on human leukemic cells potentiate fetal hemoglobin production by targeting the polyamine pathway Biochem Pharmacol 77(6):1021-1028
94. Taylor WR, White NJ (2004) Antimalarial drug toxicity: a review. Drug Saf27(1):25-61 (Pubitemid 38186936)
95. Hochstein P (1971) Glucose-6-phosphate dehydrogenase defi-ciency: mechanisms ofdrug-induced hemolysis. Exp Eye Res 11 (3):389-395
96. Kleinegger CL, Hammond HL, Finkelstein MW (2000) Oral mucosal hyperpigmentation secondary to antimalarial drug therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90 (2):189-194
97. Bortoli R, Santiago M (2007) Chloroquine ototoxicity. Clin Rheumatol 26(11):1809-1810 (Pubitemid 47516957)
98. Tehrani R, Ostrowski RA, Hariman R, Jay WM (2008) Ocular toxicity ofhydroxychloroquine. Semin Ophthalmol 23(3):201-209
99. Wolfe F, Marmor MF (2010) Rates and predictors ofhydroxy-chloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62(6):775-784
100. Costedoat-Chalumeau N, Hulot JS, Amoura Z, Delcourt A, Maisonobe T, Dorent R et al (2007) Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology 107 (2):73-80
101. Keating RJ, Bhatia S, Amin S, Williams A, Sinak LJ, Edwards WD (2005) Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction. J Am Soc Echocardiogr 18(9):981
102. Kwon JB, Kleiner A, Ishida K, Godown J, Ciafaloni E, Looney RJ Jr (2010) Hydroxychloroquine-induced myopathy J Clin Rheumatol 16(1):28-31
103. Siddiqui AK, Huberfeld SI, Weidenheim KM, Einberg KR, Efferen LS (2007) Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest 131(2):588-590 (Pubitemid 46280423)
104. Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M, Shirey E et al (1987) Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 82(3):447-455
105. Costedoat-Chalumeau N, Amoura Z, Aymard G, Le TH, Wechsler B, Vauthier D et al (2002) Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 46 (4):1123-1124 (Pubitemid 34303828)
106. Clowse ME, Magder L, Witter F, Petri M (2006) Hydroxychlor-oquine in lupus pregnancy. Arthritis Rheum 54(11):3640-3647
107. Levy M, Buskila D, Gladman DD, Urowitz MB, Koren G (1991) Pregnancy outcome following first trimester exposure to chloro-quine. Am J Perinatol 8(3):174-178
108. Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G et al (2001) Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358(9284):813-814 (Pubitemid 32868737)
109. Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A et al (2005) Follow-up of infants exposed to hydroxychlor-oquine given to mothers during pregnancy and lactation. J Perinatol 25(2):86-89 (Pubitemid 40277379)
110. Costedoat-Chalumeau N, Amoura Z, Huong DL, Lechat P, Piette JC (2005) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Auto-immun Rev 4(2):111-115 (Pubitemid 40255619)
111. cdc.gov [online] [database on the Internet]. Available from: http://www.cdc.gov/malaria/resources/pdf/treatmenttable73109. pdf. Accessed 22 Nov 2010